Experimental murine model of disseminated infection by Saksenaea vasiformis: Successful treatment with posaconazole

Medical Mycology

Volumn 50, Issue 7, 2012, Pages 710-715

  Salas, Valentina ^a   Pastor, F Javier ^a   Calvo, Enrique ^a   Sutton, Deanna ^b   García Hermoso, Dea ^c,d   Mayayo, Emilio ^a   Dromer, Françoise ^c,d   Fothergill, Anette ^b   Alvarez, Eduardo ^a   Guarro, Josep ^a  

^a FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c INSTITUT PASTEUR   (France)

^d CNRS   (France)

Author keywords

Murine model; Posaconazole; S. vasiformis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; POSACONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; FUNGUS GROWTH; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUCORALES; MUCORMYCOSIS; NONHUMAN; SAKSENAEA VASIFORMIS; SURVIVAL; SURVIVAL RATE;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; DISEASE MODELS, ANIMAL; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MUCORALES; MUCORMYCOSIS; TREATMENT OUTCOME; TRIAZOLES;

FUNGI; MURINAE; SAKSENAEA VASIFORMIS;

EID: 84866491362     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2012.673137     Document Type: Article

References (27)

1. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236-301.
2. Robeck TR, Dalton M. S aksenaea vasiformis and A pophysomyces elegans zygomycotic infections in bottlenose dolphins (Tursiops truncatus), a killer whale (Orcinus orca), and pacifi c white-sided dolphins (Lagenorhynchus obliquidens) . J Zoo Wildl Med 2002; 33: 356-366.
3. Padmaja IJ, Ramani TV, Kalyani S. Cutaneous zygomycosis: Necrotising fascitis due to Saksenaea vasiformis . Indian J Med Microbiol 2006; 24: 58-60.
4. Stewardson AJ, Holmes NE, Dellis DH, Howden BP. Cutaneous zygomycosis caused by Saksenaea vasiformis following water-related wound in a 24-year-old immunocompetent woman. Mycoses 2009; 52: 547-549.
5. Baradkar VP, Kumar S. Cutaneous Zygomycosis due to Saksenaea vasiformis in an immunocompetent host. Indian J Med Microbio 2009; 54: 382-384.
6. Vega W, Orellana M, Zaror L, Gen éJ, Guarro J. S aksenaea vasiformis infections: Case report and literature review. Mycopathologia 2006; 162: 289-294.
7. Gomes MZR, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non- Rhizopus, Mucor, and Lichtheimia species. Clin Microb Rev 2011; 24: 411-445.
8. Pierce PF, Word MB, Roberts GD, et al . Saksenaea vasiformis osteomielitis. J Clin Microbiol 1987; 25: 933-935.
9. Trotter DJ, Gonis G, Cottrill E, Coombs C. Disseminated Saksenaea vasiformis in an immunocompetent host. Med J Aust 2008; 189: 519-520.
10. Alvarez E, García-Hermoso D, Sutton DA, et al . Molecular phylogeny and proposal of two new species of the emerging pathogenic fungus Saksenaea . J Clin Microbiol 2010; 48: 4410-4416.
11. Hospenthal DR, Chung KK, Lairet K, et al . Saksenaea erythrospora infection following combat trauma. J Clin Microbiol 2011; 49: 3707-3709.
12. Spellberg BT, Walsh J, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: From bench to beside. Clin Infect Dis 2009; 48: 1743-1751.
13. Guarro J. Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi. J Antimicrob Chemothe 2011; 66: 1447-1466.
14. Clinical and Laboratory Standards Institute (CLSI). R eference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi . Approved Standard, M38-A2, 2nd edn. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
15. Clinical and Laboratory Standards Institute (CLSI). M ethod fo Antifungal Disk Diffusion Susceptibility Testing of Nondermatophyte Filamentous Fungi . Approved guideline, M51-A. Wayne, PA: Clinical and Laboratory Standards Institute, 2010.
16. Clinical and Laboratory Standards Institute (CLSI). P erformance Standards for Antifungal Disk Diffusion Susceptibility Testing o Filamentous Fungi . Informational supplement, M51-S1 (proposed). Wayne, PA: Clinical and Laboratory Standards Institute, 2009.
17. Lewis RE, Liao G, Hou J, et al . Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007; 51: 1253-1258.
18. Dannaoui E, Meis JFGM, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated Zygomycosis. Antimicrob Agents Chemother 2003; 47: 3647-3650.
19. Graybill JR, Hernandez S, Bocanegra R, Najvar LK. Antifungal therapy of murine Aspergillus terreus infection. Antimicrob Agents Chemother 2004; 48: 3515-3519.
20. Rodríguez MM, Pastor FJ, Calvo E, et al . Correlation of in vitro activity, serum levels, and in vivo effi cacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob Agents Chemother 2009; 53: 5022-5025.
21. Sun QN, Fothergill AW, McCarthy DJ, Rinaldi MG, Graybill Jr. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fl uconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581-1582.
22. Rodríguez MM, Pastor FJ, Sutton DA, et al . Correlation between in vitro activity of posaconazole and in vivo effi cacy against Rhizopus oryzae infection in mice. Antimicrob Agents Chemother 2010; 54: 1665-1669.
23. Spreghini E, Orlando F, Giannini D, Barchiesi F. I n vitro and i n vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. J Antimicrob Chemother 2010; 65: 2158-2163.
24. Salas V, Pastor F J, Calvo E, et al . In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: Poor effi cacy of posaconazole. Antimicrob Agents Chemother 2012; (doi:10.1128/AAC.05956 - 11).
25. Pastor FJ, Ru íz-Cendoya M, Puyol I, et al . I n vitro and i n vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella . Antimicrob Agents Chemother 2010; 54: 4550-4555.
26. Sun QN, Najvar LK, Bocanegra R, et al . In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002; 46: 2310-2312.
27. Imai JK, Singh G, Clemons KV, Stevens DA. Effi cacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother 2004; 48: 4063-4066.